Estimating the global demand and potential public health impact of oral antiviral

treatment stockpile for influenza pandemics: a mathematical modelling study

Alvin X. Han, PhD[1], Katina D. Hulme, PhD[1], Colin A. Russell, PhD[1]

[1]Department of Medical Microbiology and Infection Prevention, Amsterdam University

Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Corresponding author: Alvin X. Han (x.han@amsterdamumc.nl)

Summary

Background

Oral influenza antiviral drugs could potentially minimize the disease burden of a nascent

influenza pandemic prior to the availability of vaccines. Mathematical modelling is useful for

designing antiviral stockpiling options but previous studies have yielded conflicting results,

using outdated assumptions on health-seeking behavior and transmission risk reduction

effects of antivirals.

Methods

We developed a novel multiscale model that accounts for heterogeneous transmission

dynamics which depend on when individuals are treated with after infection, using recent

clinical estimates of transmission risk reduction by antivirals. We estimated the antiviral

demand of oseltamivir and baloxavir marboxil (BXM), and their corresponding reduction on

pandemic deaths in 186 countries during the first epidemic wave of the 1918 A/H1N1, 1968

A/H3N2, 2009 A/H1N1 and COVID-19-like influenza pandemics.

Findings

Across all simulated pandemic scenarios and countries, provided that drug distribution and

treatment delays are minimized, BXM doubles the median percentage of mean pandemic

deaths averted relative to oseltamivir, ranging between 37% and 68%, with ~5%–10% less

mean treatment demand at 7%–34% per-capita. Age-based drug rationing does not

meaningfully lower total antiviral demand but instead diminishes the impact of the drug

stockpile. Under limited drug availability, antivirals should be prioritized for treatment over

provision of post-exposure prophylaxis to household contacts.

Interpretation

Antiviral drug stockpiles can substantially lower the disease burden of future influenza

pandemics. Global health actors and regional organizations must act now to ensure access to

pandemic medicines before the next influenza pandemic.

Funding

Research in context

Evidence before this study

We searched PubMed and Google Scholar for peer-reviewed articles and preprints, published

up to 31 December 2024, that relate to the use of modelling to design oral influenza antiviral

stockpile sizing options for pandemic preparedness and their corresponding health and/or

economic impact, using search terms "modelling", "influenza", "pandemic", "oral antiviral",

"antiviral", "antiviral stockpile", "oseltamivir", and "baloxavir marboxil". Due to differences

in modelling frameworks and study objectives that focus either on one or a handful of

countries (i.e. no more than ten), existing studies have yielded inconsistent results, making it

difficult to synthesize current findings for meaningful public health guidance. These studies

proposed a wide range of antiviral stockpile size recommendations from covering as little as

15% of the population in the country to >140% of the population. Previous studies have also

differently concluded on the effectiveness of distributing post-exposure prophylaxis to

uninfected and/or asymptomatic individuals, from finding little benefit at reducing

transmissions to the ability to contain a nascent influenza pandemic at its source. Most

studies also liberally assumed that symptomatic individuals largely have similar health-

seeking behaviors that prompt them to seek treatment swiftly after infection, within two days

of symptom onset, which has now been shown to be far more heterogenous since the

COVID-19 pandemic. Additionally, they assumed indirectly inferred and outsized effects of

antivirals in lowering transmission risk based on post-hoc analyses of past clinical trial data.

Added value of this study

Based on a recent randomized clinical trial, baloxavir marboxil, a polymerase inhibitor that

blocks influenza viral replication and was approved for medical use in 2018, was found to

reduce transmission risk of treated index patients by 29%. Baloxavir marboxil is therefore

the first oral influenza antiviral drug to demonstrate reduction of transmission, which is

typically achieved by prophylactic use of drugs of close contacts, by treatment of the index

infected patient. We developed a novel mathematical modelling framework, parameterized

by the new clinical data alongside more grounded assumptions on health-seeking behavior

and simulated pandemic scenarios, accounting for country-specific demography and age-

structured contact rates. This is the first study to estimate the maximum oral influenza

antiviral treatment demand and the corresponding reduction in disease burden achievable

with oral antivirals in the event of a nascent influenza pandemic in 186 countries.

Implications of all the available evidence

This study suggests that baloxavir marboxil, owing to its demonstrated effectiveness in

lowering transmission risk, can be considered by governments for stockpiling to mitigate

disease burden during an influenza pandemic. If antiviral distribution is the sole intervention

measure, the maximum baloxavir marboxil demand during the first wave of an influenza

pandemic would amount to no more than 40% per-capita and can potentially averted >37% of

expected pandemic deaths. However, its impact depends on the availability and access to

baloxavir marboxil before the next pandemic, as well as the capacity to promptly and

effectively implement test-and-treat programs in the country upon pandemic initiation.

Main Text

Introduction

Influenza A viruses (IAV) remain an emerging threat to human health owing to persistent

spillover risk of novel IAV subtypes from reservoir species. Given their antiviral activity

against diverse IAV subtypes and the convenience of administration, orally or inhalation

administered influenza antiviral drugs are potentially effective countermeasures to mitigate

the impact of a nascent influenza pandemic prior to the availability of a targeted vaccine.

Several approved drugs could be considered for pandemic preparedness stockpiling,

including adamantanes, M2 ion-channel blockers preventing the initiation of viral replication,

neuraminidase inhibitors such as oseltamivir, laninamivir and zanamivir that attenuates the

release of progeny virions from infected cells, polymerase inhibitors such as baloxavir

marboxil (BXM) and favipiravir that blocks viral replication, as well as umifenovir, a fusion

inhibitor that prevents virus fusion to host cells. Although laninamivir and zanamivir are

currently recommended for post-exposure prophylactic use, the two neuraminidase inhibitors,

alongside favirpiravir and umifenovir, are not recommended by the World Health

Organization for treatment of both severe and non-severe influenza infections given little to

no effects in reducing illness duration.[1–4] Adamantanes are unlikely to be a useful primary

antiviral stockpile due to the high propensity of developing resistance among adamantane-

treated individuals.[5] Although the emergence and spread of oseltamivir and BXM resistance

are also of concern, prompt treatment with either drug reduces symptom duration and risk of

severe disease outcomes.[5,6] Both treatments are also effective post-exposure prophylactic

drugs that lower infection risk.[2] Recently, treatment with BXM has also demonstrated a

significant clinical benefit in preventing onward transmissions.[7]

Mathematical modelling is a useful tool to rationally design evidence-based antiviral

stockpiling options amidst uncertainties about the future influenza pandemic. However,

existing studies have yielded inconsistent and even conflicting results owing to differences in

modelling objectives, approaches and assumptions, making it challenging to meaningfully

synthesize their findings for public health planning. For example, focusing on treatment

demand estimation, a neuraminidase inhibitor stockpile covering ~30% of the population was

estimated to be sufficient to treat all symptomatic individuals infected by the pandemic virus

that seek care in the US during a nascent pandemic[8]. Conversely, a separate study estimated a

much larger antiviral demand covering 40-144% of the Canadian population to account for

additional contingencies such as treating non-specific infections that also present influenza-

like illness.[9] Several studies separately used decision-tree approaches and designed stockpile

size options aimed at maximizing economic benefits. In Singapore, the cost-effective

treatment-only oseltamivir stockpile size was estimated at 40-60% per-capita[10] while

Siddiqui et al. suggest that stockpiling oseltamivir for the entire population of the UK for

treatment is more prudent since the attack rate of the future pandemic virus is unknown.[11] In

contrast, a dynamic transmission model applied to ten countries, including Singapore and

UK, estimated a much smaller treatment-only oseltamivir stockpile size of 15-25% per-capita

to minimize mortality rates and economic costs while also finding little benefit in giving

antiviral prophylaxis to exposed contacts.[12] Other studies, differently conclude that restricting

antivirals for treatment is ineffective at limiting the impact of the pandemic virus,[13] or that

spread of the pandemic virus can only be constrained under widespread distribution of post-

exposure prophylaxis (PEP), covering 20-50% of exposed contacts[14] or that a nascent

pandemic can even be contained at its source if >80% of exposed contacts were given

prophylaxis.[15,16]

Previous works would likely reach different conclusions in hindsight of the COVID-19

pandemic and availability of recent clinical data. First, all of the aforementioned studies

assumed that at least 70% of symptomatic infections could be treated within two days after

symptom onset. While symptomatic individuals might readily seek care during a pandemic,[17]

healthcare seeking behavior, including the time to seeking treatment since symptom onset, is

heterogeneous, even during a pandemic,[18] predicating on sociodemographic factors and

disease severity,[19] which could in turn diminished the effectiveness of the antiviral stockpile.

Similarly, studies proposing mass distribution of PEP assume that countries can swiftly

mobilize extensive and near-complete contact tracing but this was demonstrably challenging

during the COVID-19 pandemic even in high-resource countries.[20,21] Several studies also

assume that the infectiousness of infected individuals treated with oseltamivir is reduced by

>60%[12,15,16,22] based on post-hoc analyses[23] of past clinical trial data that originally

investigated the efficacy of oseltamivir as PEP to prevent infections among uninfected

household contacts with no direct assessment of transmission risk reduction benefits of

treatment among infected index patients.[24,25] This is an overestimate as BXM, which

significantly reduces infectious viral load relative to oseltamivir,[6] is found to reduce

transmission of treated index patients to untreated contacts by 29% based on a recent

randomized clinical trial (CENTERSTONE).[7]

In this study, we developed a novel mathematical modelling framework to estimate the

maximum antiviral demand and associated impact on burden reduction when using either

BXM or oseltamivir to mitigate the initial wave of an influenza pandemic in 186 countries.

We used the latest estimates of transmission risk reduction of antivirals based on direct

measurements in clinical trials while accounting for delays and heterogeneity in treatment

administration since infection across the population. We also estimated the additional

antiviral demand and potential benefits in distributing PEP to household contacts. Finally, we

quantified how the spread of antiviral resistance could potentially impact antiviral demand

and burden reduction.

Methods

Multiscale model

We developed a discrete-time, age-structured, deterministic SIR compartmental model of

influenza transmission that can be flexibly parameterized for individual countries using

relevant demographic and age-dependent contact rate data. To compute transmission

dynamics, we adapted the multi-type renewal equation[26] that accounts for heterogeneity in

transmission due to reduction in infectiousness by antiviral treatment which effectiveness

predicates on when treatment was initiated since infection, age-dependent contact rates

between infected and uninfected individuals, susceptibility and, if given one, protection from

infection by PEP of the uninfected individuals. The infectiousness of infected individuals was

estimated by a separate target cell-limited within-host model.[27] Assuming that the pandemic

IAV has similar within-host virus replication dynamics to seasonal IAVs, we estimated the

cell infection and viral replication rate, as well as treatment effectiveness parameters of

antivirals by fitting our within-host model to the viral load measurements taken from clinical

trial for different treatment regimens (i.e. placebo, BXM or oseltamivir) that were

administered within two days after symptom onset, with[28] and without the emergence of

BXM-resistant viruses.[6] Given that we still lack a quantitative understanding of how within-

host viral load links to between-host transmission,[29] we applied three different correlative

models that were previously applied to infer infectiousness from viral load data of respiratory

viral pathogens, estimating the best-fit parameters that align with empirical effectiveness

estimates of BXM reducing onward transmission risk by 29% within five days after

treatment.[7] As all correlative models yield similar transmission dynamics (see supplementary

appendix p.2-3; multiscale model validated against US influenza season in 2017/2018), we

used the Hill equation model for all simulations and applied the best-fit parameters to

estimate the mean infectiousness of infected individuals who were treated at different times

during the course of their infection (i.e. within and beyond two days after symptom onset),

accounting for individual variances in time to symptom onset since infection, delays in

treatment since symptom onset, and whether or not resistant mutant viruses emerge after

treatment.

See supplementary appendix for the full formulation of the within- and between-host

transmission models. We also included a table of parameters and corresponding values used

(Table S1), and a summary of key modelling assumptions (Table S2) made for the between-

host transmission model.

Maximum antiviral demand

We computed the maximum mean antiviral demand for treatment, using either oseltamivir or

BXM as the sole infection control intervention, in 186 countries where age demography and

contact rates were estimated by the UN World Population Prospects[30] and Prem et al.[31]

respectively, during the first wave of four influenza pandemic scenarios with distinct basic

reproduction number, age-stratified susceptibility to infection and case fatality rates (i.e. a

severe pandemic with a W-shaped age-specific mortality curve, 1918 A/H1N1;[32,33] a

moderately severe pandemic U-shaped age-specific mortality curve, 1968 A/H3N2;[32,33] a

mild pandemic with greater relative mortality rates among adults <65 years of age, 2009

A/H1N1;[34] a severe pandemic with greater relative susceptibility and mortality rates among

adults ≥65 years of age, COVID-19;[35,36] Table S1) akin to the 1918 A/H1N1 (R_0=2.0), 1968

A/H3N2 (R_0=1.8), 2009 A/H1N1 (R_0=1.5) and an influenza pandemic with COVID-19-like

reproduction number (R_0=3.0) and disease burden but with IAV-like generation interval. We

assumed that 84% of infections were symptomatic even though prevalence of asymptomatic

influenza remains largely uncertain.[37] We also assumed that asymptomatic individuals are as

infectious as their symptomatic counterparts.

To estimate the maximum mean antiviral demand, we assumed that there were no age

restrictions in access to antivirals and that 95% of all symptomatic individuals would ideally

seek clinical intervention within two days after symptom onset, lognormally distributed

across time (i.e. mean=1 day, sd=0.6 days after symptom onset). We also assumed that an

idealized public health infrastructure was in place such that country-wide distribution of

antivirals would begin one week after the pandemic was initiated with ten infections in the

country. Given likely limited BXM supply, heterogeneity in healthcare seeking behavior, and

delays to begin treatment distribution in reality, all of which would lead to lower antiviral

demand, we would relax the aforementioned assumptions later in the study (see below).

Rapid testing would be required for same-day antiviral administration and was performed by

a moderately sensitive rapid diagnostic test (70%).[38] Given its multi-day, five-dose treatment

course, probability of adherence to oseltamivir treatment was assumed to be lower (65%)[39]

than the single-dose BXM (95%). Treated infected individuals that did not adhere to

treatment were assumed to be effectively untreated. We estimated the impact of antiviral use

by computing the total deaths reduced relative to no infection control. Total deaths during the

pandemic wave was computed based on net incidence and the corresponding pandemic case

fatality rates while accounting for mean reduction in mortality risks of treated individuals by

23% for both oseltamivir[40] and BXM, for which robust mortality risk reduction estimates is

currently lacking.

Additional simulated scenarios

We then used our model to simulate scenarios that deviate from the aforementioned idealized

case. We simulated different delays to test-and-treatment distribution since pandemic

initiation (i.e. one week, four weeks and three months). We also accounted for heterogeneity

in healthcare seeking behavior by varying time to individual treatment since symptom onset

(i.e. mean (sd) = 1.0 (0.6), 2.0 (1.2) and 5.0 (3.0) days, which correspond to 95% likelihood

of seeking test-and-treat within two, four and eight days since symptom onset respectively).

Furthermore, we simulated different BXM distribution strategies, including extending

antiviral treatment window from two to eight days, providing PEP to asymptomatic,

undiagnosed symptomatic and uninfected household members of positively-tested

individuals. While asymptomatic and undiagnosed symptomatic individuals would lower

their infectiousness by PEP similarly to symptomatic individuals treated with antivirals,

uninfected individuals would lower their likelihood of infection by 57% for ten days after

administering BXM as PEP.[41] We also scenarios where BXM supply is limited and thus

rationed for those aged 5-24 years, 25-64 years or ≥65 years only while the rest of the

population were given oseltamivir. Finally, we investigated the impact of BXM resistance

emergence and spread based on age-stratified average treatment-emergent resistance

prevalence reported for A/H1N1pdm09 (<12 years = 9.4%; ≥12 years = 2.2%)[6,42,43] and

A/H3N2 (<12 years = 21.0%; ≥12 years = 8.5%)[28,42,44] infections. BXM treatment has no

effect on within-host replication of BXM-resistant viruses, and in turn their infectiousness.

Given limited evidence that BXM-resistant virus may be fitter than their drug-sensitive

counterparts,[45–47] we conservatively assumed that BXM-resistant strains have similar within-

host viral replication fitness and between-host transmission advantage to untreated drug-

sensitive viruses. We used a Bayesian multilevel model that partially pooled simulation

results across all simulated countries and pandemic scenarios to estimate the effect size of

each factor on the deaths averted and BXM demand. See supplementary appendix for the

formulation of the within-host, transmission and multilevel models as well as their

corresponding assumptions, parameterization and priors.

Results

Maximum antiviral treatment demand and mean deaths averted

Under the idealized assumptions about possible public health infrastructure, diagnostic

testing, and drug use, the estimated reduction in deaths by the corresponding courses of

antivirals represent the maximum potential reduction in mean pandemic deaths and treatment

demand respectively. We find that BXM broadly doubles the percentage of mean pandemic

deaths averted relative to oseltamivir (Figure 1) with less treatment courses (Figure 2) across

all pandemic scenarios and countries (Figure 3). The median percentage of mean pandemic

deaths averted across all countries depends on the severity of the pandemic scenario. BXM

use could avert 68% of deaths in the relatively mild 2009 A/H1N1-like pandemic

(interquartile range (IQR) = 62% – 100%; 13 – 34 deaths averted per million people) but only

48% in a 1968 A/H3N2-like pandemic (IQR = 45% – 52%; 194 – 329 mean deaths averted

per million people), 37% in a COVID-19-like pandemic (IQR = 35% – 40%; 843 – 2,588

mean deaths averted per million people) and 44% in a 1918 A/H1N1-like pandemic (IQR =

42% – 45%; 2,798 – 2,993 mean deaths averted per million people). The corresponding

median mean per-capita demand of BXM is 7% for a 2009 A/H1N1-like pandemic (IQR =

5% – 11%; 410 – 902 million courses of BXM as per the estimated 8.2 billion world

population in 2024[30]), 24% for a 1968 A/H3N2-like pandemic (IQR = 21% – 25%; 1.7 – 2.0

billion courses), 34% for a COVID-19-like pandemic (IQR = 33% – 36%; 2.7 – 3.0 billion

courses) and 28% for a 1918 A/H1N1-like pandemic (IQR = 25% – 29%; 2.0 – 2.4 billion

courses). In contrast, oseltamivir averts median mean deaths by 35% (IQR = 31% – 41%),

27% (IQR = 26% – 28%), 23% (IQR = 23% – 24%) and 25% (IQR = 25% – 26%) for the

2009 A/H1N1-like, 1968 A/H3N2-like, COVID-19-like and 1918 A/H1N1-like influenza

pandemics respectively, while the median mean oseltamivir demand is ~5% – 10% greater

than BXM, correspondingly amounting to 32% (IQR = 28% – 33%; 2.3 – 2.7 billion courses

of oseltamivir), 28% (IQR = 25% – 30%; 2.0 – 2.5 billion courses), 36% (IQR = 35% – 37%;

2.9 – 3.0 billion courses) and 32% (IQR = 28% – 33%; 2.3 – 2.7 billion courses) per-capita

for the four pandemic scenarios.

At the country level, owing to their generally younger demography, the maximum potential

per-capita impact on disease burden by either antiviral is lower in lower-middle and low

income countries while requiring up to four times more treatment courses relative to high

income countries (Figure 3), except for the COVID-19-like pandemic scenario which, unlike

historical influenza pandemics, impacted younger individuals to a lesser extent owing to their

lower susceptibility to SARS-CoV-2 infection, and in turn, reducing the estimated antiviral

treatment demand in lower income countries. Table S3 tabulates the estimated maximum

mean antiviral treatment demand, mean rapid testing demand and the corresponding mean

deaths averted for each individual country for all four simulated pandemic scenarios.

We also performed sensitivity analyses to account for uncertainty surrounding two key

parameters, including: (1) transmission risk reduction by BXM where the 95% confidence

interval was estimated at 12% – 45%,[7] and (2) the probability of asymptomatic infection,

which we varied between 0.05 and 0.40. With greater transmission risk reduction by BXM,

mean percentage deaths averted tend to increase with decreasing antiviral demand (Figure

S1). However, the marginal changes to mean percentage deaths averted and antiviral demand

depends on the pandemic simulated, with more diffuse changes expected for milder

pandemics. Both mean percentage deaths averted and antiviral demand also decrease with

larger assumed probability of asymptomatic infection (Figure S2 and S3). BXM tends to

result in larger decreases in mean percentage deaths averted than oseltamivir because fewer

symptomatic infections are tested for treatment.

Impact of treatment delay, distribution strategies, post-exposure prophylaxis and antiviral

resistance

We subsequently investigated how pandemic death reduction and the corresponding demand

for BXM, the potentially more impactful antiviral drug, would change by deviations in reality

from idealized assumptions. We used a Bayesian multilevel model to estimate the joint

impact of these deviations (Figure 4). First, distribution of test and treatment across the

country is often delayed beyond one week since pandemic initiation in the country. Sufficient

epidemiological evidence must accumulate before a pandemic emergency can be ascertained.

Additionally, resource, logistical and public health infrastructure constraints, especially in

low-resourced countries, can further impede timely test-and-treat interventions. Excluding

pandemic- and country-specific effects, mean percentage of deaths averted by BXM

decreases by 0.9% (95% highest posterior density (HPD) = 0.1% – 1.6%) for every week of

delay to test-and-treatment distribution since the first infections in the country. This decrease

is further exacerbated under pandemic scenarios with faster growth rates, for instance each

week of distribution delay under a COVID-19-like pandemic scenario decreases mean

percentage deaths averted by 2.9% (95% HPD = 2.8% – 3.0%). Without prompt delivery and

accessibility to test-and-treatment, the theoretical utility of a pandemic oral antiviral stockpile

is greatly diminished.[48]

It is also unlikely that most infected persons would seek test-and-treatment within two days

of symptom onset on average given heterogenous healthcare seeking behavior across the

population.[18,19] For every day of delay in mean time to treatment since symptom onset across

the population, the mean population-level reduction in deaths is expected to decrease by 0.7%

(95% HPD = 0.5% – 0.8%). To mitigate the diminishing impact of individual treatment

delay, we considered extending the current indicated BXM treatment use of within two days

post-symptom onset to eight days. Leveraging BXM's rapid inhibition of viral replication,[6]

additionally treating individuals who sought treatment after two days post-symptom onset

could theoretically lower their infectiousness (Figure S4) such that mean population-level

percentage deaths averted would increase by 2.4% (95% HPD = 1.8% – 3.0%) while

requiring 2.3% (95% HPD = 0.9% – 3.6%) more per-capita courses of BXM.

Age-based rationing is a common resource saving strategy under limited drug availability.

We estimated how overall pandemic deaths and BXM demand would change, relative to the

idealized scenario of no age restriction, if BXM was differently restricted for individuals

aged 5–24 years, 25–64 years, and those ≥65 years of age only while other age groups were

allotted oseltamivir instead. Rationing BXM for different age groups leads only to trivial

changes in total antiviral (i.e. BXM and oseltamivir) demand (i.e. age group, 95% HPD: 5–24

years, -0.1% – 1.2%; 25–64 years, -0.3% – 1.4%; ≥65 years, -0.3% – 3.0%). However, BXM

demand could approximately by halved if rationed for individuals aged 5–24 years, lowered

by ~60% if given to 25–64 years only and further reduced by ~96% if only seniors ≥65 years

are given BXM, with variation depending on the pandemic and the country (Table S4).

Changes to mean percentage pandemic deaths averted depends on the age group allotted

BXM (Figure 4). If BXM is given to younger individuals aged 5–24 years only, mean

percentage pandemic deaths averted decreases by 4.7% (95% HPD = 1.6% – 7.7%). If BXM

is restricted to individuals aged 25–64 years, changes to mean percentage pandemic deaths

averted strongly depend on pandemic-specific effects with trivial country-level effects

despite the variation in age demography between countries (Figure S5). For example, if BXM

is distributed to 25–64 years only, mean percentage deaths averted would decrease by 3.3%

(95% HPD = 3.0% – 3.6%) under COVID-19-like pandemic scenario but increase by 0.8%

(95% HPD = 0.5% – 1.2%) during the 2009 A/H1N1-like pandemic which disproportionately

affected middle-aged adults[34] (Figure 4). If BXM is allotted to older individuals ≥65 years of

age only, decrease in mean percentage deaths averted depends on the pandemic scenario (i.e.

1918 A/H1N1-like, 95% HPD = -4.9% – -4.0%; 1969 A/H3N2-like, 95% HPD = -1.1% – -

0.2%; 2009 A/H1N1-like, 95% HPD = -7.9% – -7.0%; COVID-19-like, 95% HPD = -2.7%

– -1.8%; Figure 4).

Although BXM is effective as PEP,[41] swift and extensive contact tracing for PEP distribution

can be challenging to implement during a pandemic.[20,21] Under the ideal assumption of same-

day BXM administration to household contacts upon the identification of the index patient,

excluding pandemic- or country-level effects, providing BXM as PEP on top of treatment

increases mean pandemic deaths averted by 5.2% (95% HPD = 1.7% – 8.6%) while incurring

additional per-capita BXM demand by 33.8% (95% HPD = 21.6% – 47.0%). Changes in

BXM impact and demand due to PEP varies by country (Figure S5–7) where lower-income

countries, which tend to have larger mean household sizes, would benefit from PEP

distribution when mean household size is at least four members, further increasing mean

pandemic deaths averted by up to ~6%. However, realizing this benefit would require up to

~50% more per-capita BXM demand.

Multiple studies reported that seasonal IAVs readily acquire treatment-emergent BXM-

resistant mutations without a loss in viral fitness,[6,49–51,28,52] especially among children, albeit

at different rates of emergence,[49,50,52] which have been shown to be transmissible between

ferrets[52,53] and potentially between humans[51,52]. We assessed the degree to which widespread

transmission of resistance mutations could potentially diminish the impact and demand of

BXM, assuming treatment-emergent resistance prevalence at average levels observed for

seasonal A/H1N1pdm09 and A/H3N2 viruses. Under the higher prevalence of treatment-

emergent resistance akin to A/H3N2 infections, excluding pandemic- and country-level

effects, mean pandemic deaths averted by BXM could potentially decrease by 7.0% (95%

HPD = 0.1% – 13.4%) relative to no resistance emergence. Pandemics with slower growth

rates would more likely lead to wider resistance spread, as evidenced by lower total mean

percentage pandemic deaths averted (Figure 4). Conversely, resistance spread under

A/H1N1pdm09 resistance prevalence yields trivial fixed effects on mean pandemic deaths

averted (95% HPD = -8.6% – 1.5%) and is instead strongly dependent on the pandemic

scenario (Figure 4) with generally trivial country-level effects (Figure S5) despite the age

dependency of resistance emergence rates. Assuming that rapid testing does not distinguish

between drug-sensitive and -resistant viruses for treatment administration, changes in BXM

treatment demand was trivial under both treatment-emergent resistance prevalence levels (i.e.

A/H3N2, 95% HPD = 0.0% – 2.0%; A/H1N1pdm09, 95% HPD = -0.2% – 1.5%).

Discussion

While this is not the first study to develop a multi-scale model linking within-host

infectiousness to between-host influenza transmission dynamics, we are first to account for

heterogeneous health-seeking behavior and its impact on infectiousness and transmission

dynamics. This is also the first study to incorporate recent clinical estimates of transmission

risk reduction by antiviral treatment. We estimated the maximum country-specific influenza

antiviral demand for either BXM or oseltamivir and their corresponding impact in reducing

pandemic deaths during a nascent influenza pandemic for 186 countries under a single age-

structured model, resolving difficulties in either synthesizing or extrapolating findings from

previous modeling studies, which have focused on either one or a handful of countries based

on used outdated assumptions, to inform potential influenza antiviral stockpiling options that

fit country-specific needs.

Regardless of the antiviral drug, treatment-only antiviral demand maximally amounts to 20%

– 40% per-capita, with lower income countries needing more antiviral drugs, and can avert

>20% of expected pandemic deaths during the first epidemic wave of a nascent influenza

pandemic. Because of its demonstrated benefits in reducing transmission, BXM is the more

effective and treatment course-efficient antiviral drug as BXM distribution doubles the
reduction in pandemic deaths relative to oseltamivir, with the potential to avert 37% – 68% of
mean pandemic deaths, while requiring ~5% – 10% less courses of drugs. However, due to
existing patent and cost constraints on BXM, oseltamivir remains to be the more accessible
option for lower income countries. Unless global health actors, in particular high-income
countries, muster the political will to address the many challenges underlying global health
inequity,[54,55] cooperation between regional states could present opportunities to increase
affordable access to BXM, alongside other pandemic medicines and vaccines, before the next
influenza pandemic through pooled procurement mechanisms and/or technology transfer
agreements.[56] Nonetheless, procuring enough antivirals to sufficiently meet demand would
not necessarily confer the aforementioned impact estimates unless similar investments are
made to public health infrastructure to ensure prompt drug distribution across a country upon
pandemic initiation, with enough testing resources to identify most symptomatic individuals
shortly after infection.

Under limited availability, age-based rationing of BXM while providing oseltamivir to the
rest of the population can substantially lower BXM demand even though total antiviral
courses needed will likely remain unchanged. Rationing for individuals with greater risk of
mortality (i.e. the elderly) or those with greater mobility, and thus more likely to spread the
virus (i.e. young individuals), would both lead to more pandemic deaths, the magnitude of
which depends on the pandemic scenario. However, rationing BXM for the elderly could lead
to far greater reduction in BXM demand by >90%. Cost-effectiveness analyses should be
performed to determine the appropriateness of age-based rationing under different pandemic
scenarios and country-specific drug prices but are beyond the scope of this work.

Besides treatment, providing antivirals as PEP to exposed contacts could confer additional
benefits in reducing disease burden. Household members of index patients are potentially
easier contact tracing targets for PEP distribution and a recent modelling study found that
combining treatment of the index patient and PEP for exposed household members could
yield considerable reduction in burden within individual households.[57] However, given the
heightened risk of infection during a pandemic across the population, independent of country-
level effects, distributing BXM to household contacts would only lead to modest population-
level increase in mean pandemic deaths averted by ~5% while increasing mean BXM
demand by >30%. PEP would only additionally reduce disease burden in settings where the
mean household size is ≥4. Under limited drug availability and/or below the mean household

size of four, prioritizing antiviral drugs for treatment as opposed to PEP is more effective and

treatment course-efficient considering population-level outcomes.

Finally, it is important to consider the degree to which antiviral resistance attenuates impact

as it might be more prudent to limit BXM to individuals that would most likely derive

clinical benefit from treatment as opposed to mass antiviral distribution. When assuming

average treatment-emergent prevalence of BXM resistant mutations was similar to seasonal

A/H3N2 infections, mean percentage reduction in pandemic deaths under the spread of BXM

resistance was still substantial, estimated to be >24% compared to no intervention. As such,

in spite of resistance spread, mass distributing BXM for treatment could still lead to

substantial life-saving benefits. Various strategies have been proposed to potentially suppress

the spread of resistance, such as cycling the distribution of two different antiviral drugs[58] or

combining them for treatment.[59,60] Previous modelling work showed that either strategy could

work well to suppress resistance spread if the probability of resistance emergence of the

primary antiviral drug is <5%,[58] which could be the case if treatment-emergent resistance

prevalence of the pandemic virus is similar to that empirically observed for A/H1N1pdm09

infections.

There are limitations to our study. First, we used clinical observations on viral load dynamics,

treatment effectiveness and resistance prevalence measured for seasonal influenza virus

infections to parameterize our model. While a future pandemic virus can have distinct

epidemiological properties, in contrast to extrapolations considered in previous studies, we

sought to inform antiviral treatment demand and impact using a model that is grounded on

up-to-date, high-quality empirical data.

Second, aiming to provide conservative antiviral stockpile sizing options and quantify their

impact on burden reduction, we estimated the maximum demand for antiviral drugs by

assuming that they are the sole public health intervention against a nascent pandemic prior to

the availability of vaccines. However, we have also previously showed that increasing

vaccination coverage, if pre-pandemic vaccines are available, should be prioritised over mass

test-and-treat distribution as it is the more resource-efficient option to lowering pandemic

disease burden.[48] Non-pharmaceutical interventions (NPIs) such as social distancing, often

implemented during the early stages of a pandemic could also lower antiviral demand while

augmenting burden reduction. However, the effectiveness of NPIs are often context

dependent, with varying degrees of socio-economic impacts associated with different NPIs[61]

that must be carefully considered alongside the cost effectiveness of mass test-and-treat

distribution.

Third, while we accounted for imperfect sensitivity of rapid influenza diagnostic tests, we did

not consider the impact of false positives on antiviral demand and mortality reduction given

uncertainties on background influenza-like illness activity that might prompt uninfected

individuals with similar symptoms to seek test-and-treat. However, given the uniformly high

specificities of existing rapid tests (>98%),[38] false positives are unlikely going to change our

antiviral demand and impact estimates substantially.

Finally, our country-level modelling framework and results are intended to inform public

health planning and distribution of antiviral stockpiles for individual countries. We have also

only considered the impact of drug resistance spread owing to endogenous emergence of

resistant mutations within the country and not by exogenous introduction. Future work

should investigate the impact of global resistance transmission dynamics on antiviral

effectiveness.

Influenza antiviral drugs, in particular BXM given its demonstrated clinical effectiveness in

lowering transmission risks, have the potential to significantly lower the disease burden of

future influenza pandemics. We have computed the expected maximum antiviral demand for

treatment and its corresponding impact in 186 countries. We then quantified how this

theoretical demand and impact could change depending on real-world variations. Countries

could consider our demand and impact estimates to guide their antiviral stockpile sizes and

drug distribution strategies as part of pandemic preparedness planning. Global and regional

organizations could use our estimates as targets for procurement negotiations while antiviral

drug manufacturers could base their production capacity on the same estimates. However, no

single country can stockpile its way out of a global pandemic emergency. Global health

actors must act now to ensure access to pandemic medicines before the next influenza

pandemic.

Contributors

AXH and CAR contributed to conceptualization and funding acquisition. AXH contributed to

methodology, formal analysis and data curation, and wrote the original draft. AXH, KDH and

CAR contributed to investigation, validation and visualization. CAR provided supervision.

All authors reviewed and edited the manuscript.

Data sharing

The dataset and code to run all simulations and analyses are available at

https://github.com/AMC-LAEB/flu-antiviral-stockpile.

Declaration of interests

We declare no competing interests.

Acknowledgements

AXH, KDH and CAR were supported by the European Research Council NaviFlu (grant

818353). AXH and CAR were also supported by the Dutch Research Council (NWO)

Modelling for Pandemic Preparedness grant (10710062310004). AXH was supported by the

Dutch Research Council (NWO) Veni Award (09150162210121). CAR was supported by the

Dutch Research Council (NWO) Vici Award (09150182010027).

References

1 World Health Organization. Clinical practice guidelines for influenza. 2024; published
online Sept 12. https://www.who.int/publications/i/item/9789240097759 (accessed March
4, 2025).

2 Zhao Y, Gao Y, Guyatt G, *et al.* Antivirals for post-exposure prophylaxis of influenza: a
systematic review and network meta-analysis. *The Lancet* 2024; **404**: 764–72.

3 Gao Y, Guyatt G, Uyeki TM, *et al.* Antivirals for treatment of severe influenza: a
systematic review and network meta-analysis of randomised controlled trials. *The Lancet*
2024; **404**: 753–63.

4 Gao Y, Zhao Y, Liu M, *et al.* Antiviral Medications for Treatment of Nonsevere Influenza:
A Systematic Review and Network Meta-Analysis. *JAMA Intern Med* 2025; **185**: 293–
301.

5 Hayden FG, Pavia AT. Antiviral Management of Seasonal and Pandemic Influenza. *J
Infect Dis* 2006; **194**: S119–26.

6 Hayden Frederick G., Sugaya Norio, Hirotsu Nobuo, *et al.* Baloxavir Marboxil for
Uncomplicated Influenza in Adults and Adolescents. *N Engl J Med* 2018; **379**: 913–23.

7 Cowling BJ. Phase III CENTERSTONE trial of single-dose baloxavir marboxil for the
reduction of transmission of influenza in households. 2024; published online Sept 29.
https://medically.roche.com/content/dam/pdmahub/restricted/infectious-disease/options-
xii-2024/Options-XII-2024-presentation-monto-phase-III-CENTERSTONE-study-of-
single-dose.pdf.

8 O'Hagan JJ, Wong KK, Campbell AP, *et al.* Estimating the United States Demand for
Influenza Antivirals and the Effect on Severe Influenza Disease During a Potential
Pandemic. *Clin Infect Dis* 2015; **60**: S30–41.

9 Greer AL, Schanzer D. Using a Dynamic Model to Consider Optimal Antiviral Stockpile
Size in the Face of Pandemic Influenza Uncertainty. *PLOS ONE* 2013; **8**: e67253.

10 Lee V, Phua KH, Chen M, *et al.* Economics of Neuraminidase Inhibitor Stockpiling for
Pandemic Influenza, Singapore. *Emerg Infect Dis J* 2006; **12**: 95.

11 Siddiqui MR, Edmunds WJ. Cost-effectiveness of Antiviral Stockpiling and Near-Patient
Testing for Potential Influenza Pandemic. *Emerg Infect Dis J* 2008; **14**: 267.

12 Carrasco LR, Lee VJ, Chen MI, Matchar DB, Thompson JP, Cook AR. Strategies for
antiviral stockpiling for future influenza pandemics: a global epidemic-economic
perspective. *J R Soc Interface* 2011; **8**: 1307–13.

13 McCaw JM, McVernon J. Prophylaxis or treatment? Optimal use of an antiviral stockpile
during an influenza pandemic. *Math Biosci* 2007; **209**: 336–60.

14 McVernon J, McCaw JM, Nolan TM. Modelling strategic use of the national antiviral
stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic
influenza response. *Aust N Z J Public Health* 2010; **34**: 113–9.

15 Longini IM, Nizam A, Xu S, *et al.* Containing Pandemic Influenza at the Source. *Science*
2005; **309**: 1083–7.

16 Ferguson NM, Cummings DAT, Cauchemez S, *et al.* Strategies for containing an
emerging influenza pandemic in Southeast Asia. *Nature* 2005; **437**: 209–14.

17 Siegler AJ, Hall E, Luisi N, *et al.* Willingness to Seek Diagnostic Testing for SARS-CoV-
2 With Home, Drive-through, and Clinic-Based Specimen Collection Locations. *Open*
Forum Infect Dis 2020; **7**: ofaa269.

18 Graham MS, May A, Varsavsky T, *et al.* Knowledge barriers in a national symptomatic-
COVID-19 testing programme. *PLOS Glob Public Health* 2022; **2**: e0000028.

19 Peppa M, John Edmunds W, Funk S. Disease severity determines health-seeking
behaviour amongst individuals with influenza-like illness in an internet-based cohort.
BMC Infect Dis 2017; **17**: 238.

20 Clark E, Chiao EY, Amirian ES. Why Contact Tracing Efforts Have Failed to Curb
Coronavirus Disease 2019 (COVID-19) Transmission in Much of the United States. *Clin*
Infect Dis 2021; **72**: e415–9.

21 Davis EL, Lucas TCD, Borlase A, *et al.* Contact tracing is an imperfect tool for controlling
COVID-19 transmission and relies on population adherence. *Nat Commun* 2021; **12**: 5412.

22 Halloran ME, Ferguson NM, Eubank S, *et al.* Modeling targeted layered containment of an
influenza pandemic in the United States. *Proc Natl Acad Sci* 2008; **105**: 4639–44.

23 Yang Y, Longini IM Jr, Halloran ME. Design and Evaluation of Prophylactic
Interventions Using Infectious Disease Incidence Data from Close Contact Groups. *J R*
Stat Soc Ser C Appl Stat 2006; **55**: 317–30.

24 Welliver R, Monto AS, Carewicz O, *et al.* Effectiveness of Oseltamivir in Preventing
Influenza in Household ContactsA Randomized Controlled Trial. *JAMA* 2001; **285**: 748–
54.

25 Hayden FG, Belshe R, Villanueva C, *et al.* Management of Influenza in Households: A
Prospective, Randomized Comparison of Oseltamivir Treatment With or Without
Postexposure Prophylaxis. *J Infect Dis* 2004; **189**: 440–9.

26 Green WD, Ferguson NM, Cori A. Inferring the reproduction number using the renewal
equation in heterogeneous epidemics. *J R Soc Interface* 2022; **19**: 20210429.

27 Hadjichrysanthou C, Cauët E, Lawrence E, Vegvari C, de Wolf F, Anderson RM.
Understanding the within-host dynamics of influenza A virus: from theory to clinical
implications. *J R Soc Interface* 2016; **13**: 20160289.

28 Uehara T, Hayden FG, Kawaguchi K, *et al.* Treatment-Emergent Influenza Variant
Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic
Outcomes in Uncomplicated Influenza. *J Infect Dis* 2020; **221**: 346–55.

29 Handel A, Rohani P. Crossing the scale from within-host infection dynamics to between-
host transmission fitness: a discussion of current assumptions and knowledge. *Philos*
Trans R Soc B Biol Sci 2015; **370**: 20140302.

30 United Nations. World Population Prospects. 2024. https://population.un.org/wpp/
(accessed Jan 6, 2025).

31 Prem K, Zandvoort K van, Klepac P, *et al.* Projecting contact matrices in 177 geographical
regions: An update and comparison with empirical data for the COVID-19 era. *PLOS*
Comput Biol 2021; **17**: e1009098.

32 Luk J, Gross P, Thompson WW. Observations on Mortality during the 1918 Influenza
Pandemic. *Clin Infect Dis* 2001; **33**: 1375–8.

33 Taubenberger J, Morens D. 1918 Influenza: the Mother of All Pandemics. *Emerg Infect*
Dis J 2006; **12**: 15.

34 Dawood FS, Iuliano AD, Reed C, *et al.* Estimated global mortality associated with the first
12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study.
Lancet Infect Dis 2012; **12**: 687–95.

35 Zhang J, Litvinova M, Liang Y, *et al.* Changes in contact patterns shape the dynamics of
the COVID-19 outbreak in China. *Science* 2020; **368**: 1481–6.

36 Verity R, Okell LC, Dorigatti I, *et al.* Estimates of the severity of coronavirus disease
2019: a model-based analysis. *Lancet Infect Dis* 2020; **20**: 669–77.

37 Leung NHL, Xu C, Ip DKM, Cowling BJ. Review Article: The Fraction of Influenza Virus
Infections That Are Asymptomatic: A Systematic Review and Meta-analysis.
Epidemiology 2015; **26**.
https://journals.lww.com/epidem/fulltext/2015/11000/review_article__the_fraction_of_infl
uenza_virus.13.aspx.

38 Merckx J, Wali R, Schiller I, *et al.* Diagnostic Accuracy of Novel and Traditional Rapid
Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain
Reaction. *Ann Intern Med* 2017; **167**: 394–409.

39 Smith LE, D'Antoni D, Jain V, Pearce JM, Weinman J, Rubin GJ. A systematic review of
factors affecting intended and actual adherence with antiviral medication as treatment or
prophylaxis in seasonal and pandemic flu. *Influenza Other Respir Viruses* 2016; **10**: 462–
78.

40 Hsu J, Santesso N, Mustafa R, *et al.* Antivirals for Treatment of Influenza. *Ann Intern Med*
2012; **156**: 512–24.

41 Ikematsu Hideyuki, Hayden Frederick G., Kawaguchi Keiko, *et al.* Baloxavir Marboxil for
Prophylaxis against Influenza in Household Contacts. *N Engl J Med* 2020; **383**: 309–20.

42 Baker J, Block SL, Matharu B, *et al.* Baloxavir Marboxil Single-dose Treatment in
Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3
Safety and Efficacy Trial (miniSTONE-2). *Pediatr Infect Dis J* 2020; **39**.

https://journals.lww.com/pidj/fulltext/2020/08000/baloxavir_marboxil_single_dose_treatm
ent_in.12.aspx.

43 Hirotsu N, Sakaguchi H, Fukao K, *et al.* Baloxavir safety and clinical and virologic
outcomes in influenza virus-infected pediatric patients by age group: age-based pooled
analysis of two pediatric studies conducted in Japan. *BMC Pediatr* 2023; **23**: 35.

44 Ison MG, Portsmouth S, Yoshida Y, *et al.* Early treatment with baloxavir marboxil in
high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2):
a randomised, placebo-controlled, phase 3 trial. *Lancet Infect Dis* 2020; **20**: 1204–14.

45 Checkmahomed L, M'hamdi Z, Carbonneau J, *et al.* Impact of the Baloxavir-Resistant
Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza
A(H1N1)pdm09 and A(H3N2) Strains. *J Infect Dis* 2020; **221**: 63–70.

46 Jones JC, Zagribelnyy B, Pascua PNQ, *et al.* Influenza A virus polymerase acidic protein
E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact
on replication and transmission. *PLOS Pathog* 2022; **18**: e1010698.

47 Hickerson Brady T., Petrovskaya Svetlana N., Dickensheets Harold, Donnelly Raymond
P., Ince William L., Ilyushina Natalia A. Impact of Baloxavir Resistance-Associated
Substitutions on Influenza Virus Growth and Drug Susceptibility. *J Virol* 2023; **97**:
e00154-23.

48 Han AX, Hannay E, Carmona S, Rodriguez B, Nichols BE, Russell CA. Estimating the
potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs.
Nat Commun 2023; **14**: 7981.

49 Omoto S, Speranzini V, Hashimoto T, *et al.* Characterization of influenza virus variants
induced by treatment with the endonuclease inhibitor baloxavir marboxil. *Sci Rep* 2018; **8**:
9633.

50 Takashita E, Kawakami C, Morita H, *et al.* Detection of influenza A(H3N2) viruses
exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor
baloxavir in Japan, December 2018. Eurosurveillance. 2019; **24**: 1800698.

51 Takashita E, Ichikawa M, Morita H, *et al.* Human-to-Human Transmission of Influenza
A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. *Emerg
Infect Dis J* 2019; **25**: 2108.

52 Imai M, Yamashita M, Sakai-Tagawa Y, *et al.* Influenza A variants with reduced
susceptibility to baloxavir isolated from Japanese patients are fit and transmit through
respiratory droplets. *Nat Microbiol* 2020; **5**: 27–33.

53 Jones JC, Pascua PNQ, Fabrizio TP, *et al.* Influenza A and B viruses with reduced
baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
Proc Natl Acad Sci 2020; **117**: 8593–601.

54 Lavery JV, Porter RM, Addiss DG. Cascading failures in COVID-19 vaccine equity.
Science 2023; **380**: 460–2.

55 Pai M, Bandara S, Kyobutungi C. Shifting power in global health will require leadership
by the Global South and allyship by the Global North. *The Lancet* 2024; **404**: 1711–3.

56 Rahman-Shepherd A, Aghogho Evaborhene N, Berman A, *et al.* Establishing the value of
regional cooperation and a critical role for regional organisations in managing future
health emergencies. *Lancet Glob Health* 2025; **13**: e585–92.

57 Zaaraoui H, Schumer C, Duval X, Hoen B, Opatowski L, Guedj J. Modelling the
effectiveness of antiviral treatment strategies to prevent household transmission of acute
respiratory viruses. *PLOS Comput Biol* 2024; **20**: e1012573.

58 Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S. Hedging against Antiviral Resistance
during the Next Influenza Pandemic Using Small Stockpiles of an Alternative
Chemotherapy. *PLOS Med* 2009; **6**: e1000085.

59 Park J-H, Kim B, Antigua KJC, *et al.* Baloxavir-oseltamivir combination therapy inhibits
the emergence of resistant substitutions in influenza A virus PA gene in a mouse model.
Antiviral Res 2021; **193**: 105126.

60 Koszalka Paulina, George Ankita, Dhanasekaran Vijaykrishna, Hurt Aeron C., Subbarao
Kanta. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza
Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model. *mBio* 2022; **13**:
e01056-22.

61 Haug N, Geyrhofer L, Londei A, *et al.* Ranking the effectiveness of worldwide COVID-19
government interventions. *Nat Hum Behav* 2020; **4**: 1303–12.

Figures

Figure 1: Mean percentage deaths averted by test-and-treat with oral antivirals in 186

countries under idealized assumptions. Baloxavir marboxil (BXM; left column) or

oseltamivir (OSL; right column) was administered to all individuals that were positively

diagnosed, using a rapid test with 70% test sensitivity, within two days of symptom onset. All

symptomatic individuals were assumed to have sought testing within one day after symptom

onset on average. Distribution of oral antivirals for treatment began one week after the

pandemic was initiated in the country with ten infections. (**A**) 1918 A/H1N1 pandemic

(=2.0). (**B**) Hypothetical influenza pandemic with COVID-19-like disease burden (=3.0)

but generation interval akin to seasonal influenza viruses.

Figure 2: Maximum treatment oral antiviral demand of 186 countries under idealized assumptions. Baloxavir marboxil (BXM; left column) or oseltamivir (OSL; right column) was administered to all individuals that were positively diagnosed, using a rapid test with 70% test sensitivity, within two days of symptom onset. All symptomatic individuals were assumed to have sought testing within one day after symptom onset on average. Distribution of oral antivirals for treatment began one week after the pandemic was initiated in the country with ten infections. (**A**) 1918 A/H1N1 pandemic (=2.0). (**B**) Hypothetical influenza pandemic with COVID-19-like disease burden (=3.0) but generation interval akin to seasonal influenza viruses.

Figure 3: Demographic and economic covariates to treatment oral antiviral demand and impact. Mean percentage deaths averted (left column) and maximum treatment oral antiviral demand (right column) for each country (circle, shading denotes median age of country's population) under different pandemic scenarios (denoted by color of circles; red, 1918 A/H1N1; green, 1968 A/H3N2; blue, 2009 A/H1N1; and purple, COVID-19-like) are plotted against their gross national income (GNI) per capita is US dollars (USD) in 2023. Background shading denotes the range of GNI per capita distinguishing between different country income groups as classified by the World Bank in 2024 (low income country, LIC; lower-middle income country, LMIC; upper-middle income country, UMIC; and high income country, HIC). Antiviral drugs were administered to all individuals that were positively diagnosed, using a rapid test with 70% test sensitivity, within two days of symptom onset. All symptomatic individuals were assumed to have sought testing within one day after symptom onset on average. Distribution of oral antivirals for treatment began one week after the pandemic was initiated in the country with ten infections. (**A**) Baloxavir marboxil. (**B**) Oseltamivir.

Figure 4: Joint effects of treatment delays, distribution strategies, post-exposure prophylaxis and antiviral resistance on mean percentage deaths averted and total antiviral demand. Relative to the idealized scenario (i.e. antivirals are swiftly distributed to patients across the country one week after the first infection in the country, with no limits on access and availability of tests and antivirals; >95% of all symptomatic individuals are treated within two days after symptom onset if positively diagnosed by a rapid diagnostic test; No emergence and spread of BXM-resistant viruses), mean posterior changes in mean percentage deaths averted (left plot) and total antiviral (i.e. BXM and oseltamivir) demand (right plot) across pandemics and countries are plotted as black circles (i.e. fixed effects) while the thick and thin lines denote the corresponding 67% and 95% highest posterior density intervals respectively. The corresponding pandemic scenario-adjusted posterior effects are plotted alongside (posterior mean and 95% highest posterior density interval denoted by color of circle and line respectively; red, 1918 A/H1N1; green, 1968 A/H3N2; blue, 2009 A/H1N1; and purple, COVID-19-like).

745